Pular para o conteúdo principal
Ranking Invest

IONS - Ionis Pharmaceuticals, Inc.

Segmento: HealthcareIonis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Análise Ranking Invest

Valor de Mercado
$ 7.31 Bi
IVR
-0.12Índice proprietário de comparação relativa: -0,12.
IVR2
-0.19Leitura proprietária complementar: -19%.
MLL
-0.19Leitura proprietária complementar: -19%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 439.74 Mi

Dívida Líquida

-$ 350.06 Mi

L4T

-$ 565.17 Mi

MM4T

-68.82%

Indicadores Básicos

ROE

-128.53%

Índices de Previsibilidade

Receita Líquida

E0.26

Lucro

D0.53

Margem

D0.63

Índices de Tendência

Receita Líquida

C4.57

Lucro

E-2.00

Margem

D-0.51

Índices de Endividamento

DIV/PAT

-0.80

DIV/L4T

0.62

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.